首页 > 最新文献

Lancet Hiv最新文献

英文 中文
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. 抗hiv -1单克隆抗体PGT121.414的安全性、耐受性、药代动力学和中和活性LS单独或联合VRC07-523LS治疗美国无HIV成人(HVTN 136/HPTN 092):一项首次人体、开放标签、随机对照的1期临床试验。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-01-01 Epub Date: 2024-12-10 DOI: 10.1016/S2352-3018(24)00247-9
Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez, Chenchen Yu, Catherine Yen, Brett Hanscom, Zonglin He, Maurine D Miner, Theresa Gamble, Jack Heptinstall, Kelly E Seaton, Elizabeth Domin, Bob C Lin, Krisha McKee, Nicole Doria-Rose, Stephanie Regenold, Hans Spiegel, Maija Anderson, Nadia McClosky, Lily Zhang, Estelle Piwowar-Manning, Margaret E Ackerman, Michael Pensiero, Bonnie J Dye, Raphael J Landovitz, Kenneth Mayer, Marc Siegel, Magdalena Sobieszczyk, Stephen R Walsh, Lucio Gama, Dan H Barouch, David C Montefiori, Georgia D Tomaras
<p><strong>Background: </strong>Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics in adults.</p><p><strong>Methods: </strong>In this first-in-human phase 1 trial (HVTN 136/HPTN 092), adults without HIV were enrolled at six university-affiliated clinical research sites in the USA. Part A evaluated escalating single intravenous doses or subcutaneous infusion of PGT121.414.LS, in four groups: 3 mg/kg intravenous (treatment group 1; n=3), 10 mg/kg intravenous (treatment group 2; n=4), 30 mg/kg intravenous (treatment group 3; n=3), and 5 mg/kg subcutaneous (treatment group 4; n=3). Part B evaluated repeated sequential intravenous administrations of 20 mg/kg PGT121.414.LS plus 20 mg/kg VRC07-523LS (treatment group 5; n=10) and sequential subcutaneous administrations of 5 mg/kg PGT121.414.LS plus 5 mg/kg VRC07-523LS (treatment group 6; n=10) on days 0, 112, and 224. Participants in treatment groups 1 and 2 were enrolled sequentially, with participants enrolled and randomly assigned to treatment groups 3 and 4 after a review of safety data. Participants in treatment groups 5 and 6 were randomly assigned in blocks after a review of safety data from treatment groups 1-4. The primary endpoints were safety and tolerability of mAbs, serum concentrations and pharmacokinetics of mAbs, and serum neutralising activity, assessed in participants who received all scheduled product administrations. Serum concentrations of each mAb were measured via a multiplex assay, and neutralisation activity against multiple HIV viruses was measured via the TZM-bl assay. Serum concentrations were estimated via an open, two-compartment model with first-order elimination from the central compartment. This study was registered with ClinicalTrials.gov (NCT04212091) and has been completed.</p><p><strong>Findings: </strong>Between Nov 10, 2020, and Oct 5, 2021, we enrolled 33 participants without HIV: median age was 31 years (range 22-48); 19 were assigned female sex at birth and 11 were assigned male sex at birth. Three participants and four participants were sequentially assigned to treatment groups 1 and 2, respectively, and, after safety review, six participants were randomly assigned to treatment groups 3 (n=3) and 4 (n=3); after safety review, 20 participants were randomly assigned to treatment groups 5 (n=10) and 6 (n=10). Intravenous and subcutaneous infusions were safe and well tolerated, without serious adverse events or dose-limiting toxicities. Dose escalation of PGT121.414.LS from 3 mg/kg to 30 mg/kg (intravenous) resulted in a dose-proportional increase in serum concentration of PGT121.414.LS, whether administered alone or in combination with VRC07-523LS. The estimated elimination half-life of PGT121.414.LS was 71 days (95% CI 66-75), three times that of its parental form, PGT121. The estimated subcutaneous (vs intraveno
背景:目前正在开发多种用于预防 HIV-1 的广谱中和单克隆抗体 (mAbs)。本试验的目的是测试 PGT121.414.LS 和 VRC07-523LS mAbs 在成人中的安全性和药代动力学:在这项首次人体 1 期试验(HVTN 136/HPTN 092)中,美国六所大学附属临床研究机构招募了未感染艾滋病毒的成年人。A 部分评估了单次静脉注射或皮下注射 PGT121.414.LS 的递增剂量,分为四组:3 毫克/千克静脉注射(治疗组 1;n=3)、10 毫克/千克静脉注射(治疗组 2;n=4)、30 毫克/千克静脉注射(治疗组 3;n=3)和 5 毫克/千克皮下注射(治疗组 4;n=3)。B 部分评估了在第 0、112 和 224 天重复连续静脉注射 20 mg/kg PGT121.414.LS 加 20 mg/kg VRC07-523LS(治疗组 5;n=10)和连续皮下注射 5 mg/kg PGT121.414.LS 加 5 mg/kg VRC07-523LS(治疗组 6;n=10)的情况。第 1 和第 2 治疗组的参与者是按顺序注册的,在对安全性数据进行审查后注册并随机分配到第 3 和第 4 治疗组。治疗组 5 和 6 的参与者是在审查了治疗组 1-4 的安全性数据后分块随机分配的。主要终点为 mAb 的安全性和耐受性、mAb 的血清浓度和药代动力学以及血清中和活性,对接受了所有预定产品给药的参与者进行评估。每种 mAb 的血清浓度通过多重检测法进行测定,对多种 HIV 病毒的中和活性通过 TZM-bl 检测法进行测定。血清浓度通过开放式二室模型估算,中心室为一阶消除。该研究已在 ClinicalTrials.gov 注册(NCT04212091),并已完成:2020 年 11 月 10 日至 2021 年 10 月 5 日期间,我们招募了 33 名未感染艾滋病毒的参与者:中位年龄为 31 岁(22-48 岁不等);19 人出生时性别为女性,11 人出生时性别为男性。3名参与者和4名参与者分别被顺序分配到治疗组1和治疗组2,经过安全性审查后,6名参与者被随机分配到治疗组3(n=3)和治疗组4(n=3);经过安全性审查后,20名参与者被随机分配到治疗组5(n=10)和治疗组6(n=10)。静脉注射和皮下注射安全且耐受性良好,未出现严重不良事件或剂量限制性毒性反应。PGT121.414.LS的剂量从3毫克/千克增加到30毫克/千克(静脉注射)后,无论是单独给药还是与VRC07-523LS联合给药,PGT121.414.LS的血清浓度都会按剂量比例增加。PGT121.414.LS 的估计消除半衰期为 71 天(95% CI 66-75),是其母体 PGT121 的三倍。PGT121.414.LS的皮下(与静脉注射)生物利用度估计为86-1%(95% CI 64-0-95-5)。高剂量组和双重组合静脉注射组的中和活性高于皮下注射组:这些发现支持进一步评估 PGT121.414.LS 与其他 mAbs 联用预防 HIV-1 的效果:美国国立过敏与传染病研究所和美国国立卫生研究院。
{"title":"Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.","authors":"Srilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, Yunda Huang, Carmen A Paez, Chenchen Yu, Catherine Yen, Brett Hanscom, Zonglin He, Maurine D Miner, Theresa Gamble, Jack Heptinstall, Kelly E Seaton, Elizabeth Domin, Bob C Lin, Krisha McKee, Nicole Doria-Rose, Stephanie Regenold, Hans Spiegel, Maija Anderson, Nadia McClosky, Lily Zhang, Estelle Piwowar-Manning, Margaret E Ackerman, Michael Pensiero, Bonnie J Dye, Raphael J Landovitz, Kenneth Mayer, Marc Siegel, Magdalena Sobieszczyk, Stephen R Walsh, Lucio Gama, Dan H Barouch, David C Montefiori, Georgia D Tomaras","doi":"10.1016/S2352-3018(24)00247-9","DOIUrl":"10.1016/S2352-3018(24)00247-9","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics in adults.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this first-in-human phase 1 trial (HVTN 136/HPTN 092), adults without HIV were enrolled at six university-affiliated clinical research sites in the USA. Part A evaluated escalating single intravenous doses or subcutaneous infusion of PGT121.414.LS, in four groups: 3 mg/kg intravenous (treatment group 1; n=3), 10 mg/kg intravenous (treatment group 2; n=4), 30 mg/kg intravenous (treatment group 3; n=3), and 5 mg/kg subcutaneous (treatment group 4; n=3). Part B evaluated repeated sequential intravenous administrations of 20 mg/kg PGT121.414.LS plus 20 mg/kg VRC07-523LS (treatment group 5; n=10) and sequential subcutaneous administrations of 5 mg/kg PGT121.414.LS plus 5 mg/kg VRC07-523LS (treatment group 6; n=10) on days 0, 112, and 224. Participants in treatment groups 1 and 2 were enrolled sequentially, with participants enrolled and randomly assigned to treatment groups 3 and 4 after a review of safety data. Participants in treatment groups 5 and 6 were randomly assigned in blocks after a review of safety data from treatment groups 1-4. The primary endpoints were safety and tolerability of mAbs, serum concentrations and pharmacokinetics of mAbs, and serum neutralising activity, assessed in participants who received all scheduled product administrations. Serum concentrations of each mAb were measured via a multiplex assay, and neutralisation activity against multiple HIV viruses was measured via the TZM-bl assay. Serum concentrations were estimated via an open, two-compartment model with first-order elimination from the central compartment. This study was registered with ClinicalTrials.gov (NCT04212091) and has been completed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Nov 10, 2020, and Oct 5, 2021, we enrolled 33 participants without HIV: median age was 31 years (range 22-48); 19 were assigned female sex at birth and 11 were assigned male sex at birth. Three participants and four participants were sequentially assigned to treatment groups 1 and 2, respectively, and, after safety review, six participants were randomly assigned to treatment groups 3 (n=3) and 4 (n=3); after safety review, 20 participants were randomly assigned to treatment groups 5 (n=10) and 6 (n=10). Intravenous and subcutaneous infusions were safe and well tolerated, without serious adverse events or dose-limiting toxicities. Dose escalation of PGT121.414.LS from 3 mg/kg to 30 mg/kg (intravenous) resulted in a dose-proportional increase in serum concentration of PGT121.414.LS, whether administered alone or in combination with VRC07-523LS. The estimated elimination half-life of PGT121.414.LS was 71 days (95% CI 66-75), three times that of its parental form, PGT121. The estimated subcutaneous (vs intraveno","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e13-e25"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fostering healthy cognitive ageing in people living with HIV. 促进艾滋病毒感染者健康的认知老龄化。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-29 DOI: 10.1016/S2352-3018(24)00248-0
Lucette A Cysique, Jules Levin, Chris Howard, Jeff Taylor, John Rule, Jane Costello, Jane Bruning, Priscilla Njeri, Amy B Mullens, Edwina Wright, Hetta Gouse, Kirstie Daken, Mattia Trunfio, Htein Linn Aung, Reuben N Robbins, Christopher M Ferraris, Jose A Muñoz-Moreno, Steven P Woods, David J Moore, Christopher Power, Pui Li Wong, Kejal Hasmukharay, Primrose Nyamayaro, Jaime Vera, Reena Rajasuriar, Robert K Heaton, Karl Goodkin, Scott Letendre, Ronald J Ellis, Bruce J Brew, Sean B Rourke

Prevalence and incidence of HIV among people aged 50 years and older continue to rise worldwide, generating increasing awareness among care providers, scientists, and the HIV community about the importance of brain health in older adults with HIV. Many age-related factors that adversely affect brain health can occur earlier and more often among people with HIV, including epigenetic ageing, chronic medical conditions (eg, cardiovascular disease), and age-related syndromes (eg, frailty). Extensive dialogue between HIV community leaders, health-care providers, and scientists has led to the development of a multidimensional response strategy to protect and enhance brain health in people ageing with HIV that spans across public health, clinical spaces, and research spaces. This response strategy was informed by integrated ageing care frameworks and is centred on prevention, early detection, and management of brain health issues associated with HIV (eg, neurocognitive disorders), with specific considerations for low-resource or middle-resource countries. A collaborative, international, and data-informed update of the diagnostic criteria for HIV-associated neurocognitive disorders is a cornerstone of the proposed response strategy. The proposed response strategy includes a dynamic, international, online knowledge hub that will provide a crucial community resource for emerging evidence on the brain health of people ageing with HIV.

全球50岁及以上人群中艾滋病毒的流行率和发病率持续上升,使护理人员、科学家和艾滋病毒社区越来越意识到老年艾滋病毒感染者大脑健康的重要性。在艾滋病毒感染者中,许多对大脑健康产生不利影响的与年龄有关的因素可能更早、更频繁地出现,包括表观遗传衰老、慢性疾病(如心血管疾病)和与年龄有关的综合症(如虚弱)。艾滋病毒社区领导人、卫生保健提供者和科学家之间的广泛对话导致制定了一项多维应对战略,以保护和加强跨越公共卫生、临床空间和研究空间的老年艾滋病毒感染者的大脑健康。这一应对战略以综合老龄护理框架为依据,重点是预防、早期发现和管理与艾滋病毒有关的大脑健康问题(如神经认知障碍),并特别考虑到资源匮乏或资源中等的国家。对艾滋病毒相关神经认知障碍的诊断标准进行合作、国际和数据知情的更新是拟议应对策略的基石。拟议的应对战略包括一个动态的国际在线知识中心,该中心将为有关艾滋病毒感染者老年大脑健康的新证据提供重要的社区资源。
{"title":"Fostering healthy cognitive ageing in people living with HIV.","authors":"Lucette A Cysique, Jules Levin, Chris Howard, Jeff Taylor, John Rule, Jane Costello, Jane Bruning, Priscilla Njeri, Amy B Mullens, Edwina Wright, Hetta Gouse, Kirstie Daken, Mattia Trunfio, Htein Linn Aung, Reuben N Robbins, Christopher M Ferraris, Jose A Muñoz-Moreno, Steven P Woods, David J Moore, Christopher Power, Pui Li Wong, Kejal Hasmukharay, Primrose Nyamayaro, Jaime Vera, Reena Rajasuriar, Robert K Heaton, Karl Goodkin, Scott Letendre, Ronald J Ellis, Bruce J Brew, Sean B Rourke","doi":"10.1016/S2352-3018(24)00248-0","DOIUrl":"10.1016/S2352-3018(24)00248-0","url":null,"abstract":"<p><p>Prevalence and incidence of HIV among people aged 50 years and older continue to rise worldwide, generating increasing awareness among care providers, scientists, and the HIV community about the importance of brain health in older adults with HIV. Many age-related factors that adversely affect brain health can occur earlier and more often among people with HIV, including epigenetic ageing, chronic medical conditions (eg, cardiovascular disease), and age-related syndromes (eg, frailty). Extensive dialogue between HIV community leaders, health-care providers, and scientists has led to the development of a multidimensional response strategy to protect and enhance brain health in people ageing with HIV that spans across public health, clinical spaces, and research spaces. This response strategy was informed by integrated ageing care frameworks and is centred on prevention, early detection, and management of brain health issues associated with HIV (eg, neurocognitive disorders), with specific considerations for low-resource or middle-resource countries. A collaborative, international, and data-informed update of the diagnostic criteria for HIV-associated neurocognitive disorders is a cornerstone of the proposed response strategy. The proposed response strategy includes a dynamic, international, online knowledge hub that will provide a crucial community resource for emerging evidence on the brain health of people ageing with HIV.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e71-e80"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex as a biological variable in HIV-1 and schistosome co-infection. 性别是 HIV-1 和血吸虫共同感染的一个生物变量。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2025-01-01 Epub Date: 2024-10-25 DOI: 10.1016/S2352-3018(24)00234-0
Jane K Maganga, Khanh Pham, John M Changalucha, Jennifer A Downs

The sex of people living with HIV-1 infection, schistosome infection, or both, is a fundamental determinant of their clinical outcomes and of how these two infections interact in the host. Data from longitudinal and cross-sectional human studies and animal models indicate that males with HIV-1 and schistosome co-infection excrete fewer schistosome eggs and might have higher HIV-1 RNA viral loads and greater liver damage. Females with schistosome infection appear to have higher risk of HIV-1 acquisition than females without, particularly in Schistosoma haematobium infection, and a greater risk of death in HIV-1 and schistosome co-infection. Greater transmission of HIV-1 to partners has been shown in both sexes in those with schistosome infection. Biological sex is a consequential factor affecting pathophysiological and clinical responses in HIV-1 and schistosome co-infection. Designing future analyses to incorporate sex is vital to optimise research and care for people living with HIV-1, schistosomes, and HIV-1 and schistosome co-infection.

HIV-1感染者、血吸虫感染者或同时感染者的性别是决定其临床结果以及这两种感染如何在宿主体内相互作用的根本因素。纵向和横断面人体研究及动物模型的数据表明,男性 HIV-1 感染者和血吸虫合并感染者排出的血吸虫卵较少,HIV-1 RNA 病毒载量可能较高,肝脏损伤可能较大。女性血吸虫感染者感染 HIV-1 病毒的风险似乎高于非血吸虫感染者,尤其是血吸虫感染者。在血吸虫感染者中,男女双方都会将 HIV-1 传播给伴侣。生物性别是影响 HIV-1 和血吸虫合并感染的病理生理和临床反应的一个重要因素。在设计未来的分析时纳入性别因素对于优化对 HIV-1、血吸虫以及 HIV-1 和血吸虫合并感染者的研究和护理至关重要。
{"title":"Sex as a biological variable in HIV-1 and schistosome co-infection.","authors":"Jane K Maganga, Khanh Pham, John M Changalucha, Jennifer A Downs","doi":"10.1016/S2352-3018(24)00234-0","DOIUrl":"10.1016/S2352-3018(24)00234-0","url":null,"abstract":"<p><p>The sex of people living with HIV-1 infection, schistosome infection, or both, is a fundamental determinant of their clinical outcomes and of how these two infections interact in the host. Data from longitudinal and cross-sectional human studies and animal models indicate that males with HIV-1 and schistosome co-infection excrete fewer schistosome eggs and might have higher HIV-1 RNA viral loads and greater liver damage. Females with schistosome infection appear to have higher risk of HIV-1 acquisition than females without, particularly in Schistosoma haematobium infection, and a greater risk of death in HIV-1 and schistosome co-infection. Greater transmission of HIV-1 to partners has been shown in both sexes in those with schistosome infection. Biological sex is a consequential factor affecting pathophysiological and clinical responses in HIV-1 and schistosome co-infection. Designing future analyses to incorporate sex is vital to optimise research and care for people living with HIV-1, schistosomes, and HIV-1 and schistosome co-infection.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e60-e70"},"PeriodicalIF":12.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11710965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. 204个国家和地区1990-2021年全球、区域和国家艾滋病毒/艾滋病负担以及到2050年的预测:《2021年全球疾病负担研究》。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1016/S2352-3018(24)00212-1
<p><strong>Background: </strong>As set out in Sustainable Development Goal 3.3, the target date for ending the HIV epidemic as a public health threat is 2030. Therefore, there is a crucial need to evaluate current epidemiological trends and monitor global progress towards HIV incidence and mortality reduction goals. In this analysis, we assess the current burden of HIV in 204 countries and territories and forecast HIV incidence, prevalence, and mortality up to 2050 to allow countries to plan for a sustained response with an increasing number of people living with HIV globally.</p><p><strong>Methods: </strong>We used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 analytical framework to compute age-sex-specific HIV mortality, incidence, and prevalence estimates for 204 countries and territories (1990-2021). We aimed to analyse all available data sources, including data on the provision of HIV programmes reported to UNAIDS, published literature on mortality among people on antiretroviral therapy (ART) identified by a systematic review, household surveys, sentinel surveillance antenatal care clinic data, vital registration data, and country-level case report data. We calibrated a mechanistic simulation of HIV infection and natural history to available data to estimate HIV burden from 1990 to 2021 and generated forecasts to 2050 through projection of all simulation inputs into the future. Historical outcomes (1990-2021) were simulated at the 1000-draw level to support propagation of uncertainty and reporting of uncertainty intervals (UIs). Our approach to forecasting utilised the transmission rate as the basis for projection, along with new rate-of-change projections of ART coverage. Additionally, we introduced two new metrics to our reporting: prevalence of unsuppressed viraemia (PUV), which represents the proportion of the population without a suppressed level of HIV (viral load <1000 copies per mL), and period lifetime probability of HIV acquisition, which quantifies the hypothetical probability of acquiring HIV for a synthetic cohort, a simulated population that is aged from birth to death through the set of age-specific incidence rates of a given time period.</p><p><strong>Findings: </strong>Global new HIV infections decreased by 21·9% (95% UI 13·1-28·8) between 2010 and 2021, from 2·11 million (2·02-2·25) in 2010 to 1·65 million (1·48-1·82) in 2021. HIV-related deaths decreased by 39·7% (33·7-44·5), from 1·19 million (1·07-1·37) in 2010 to 718 000 (669 000-785 000) in 2021. The largest declines in both HIV incidence and mortality were in sub-Saharan Africa and south Asia. However, super-regions including central Europe, eastern Europe, and central Asia, and north Africa and the Middle East experienced increasing HIV incidence and mortality rates. The number of people living with HIV reached 40·0 million (38·0-42·4) in 2021, an increase from 29·5 million (28·1-31·0) in 2010. The lifetime probability of HIV acquisition
背景:正如可持续发展目标3.3所述,终止作为公共卫生威胁的艾滋病毒流行的具体日期是2030年。因此,非常有必要评估当前的流行病学趋势,并监测全球在实现减少艾滋病毒发病率和死亡率目标方面取得的进展。在本分析中,我们评估了204个国家和地区目前的艾滋病毒负担,并预测了到2050年的艾滋病毒发病率、流行率和死亡率,以便各国在全球艾滋病毒感染者人数不断增加的情况下制定持续应对计划。方法:我们使用全球疾病、伤害和风险因素负担研究(GBD) 2021分析框架来计算204个国家和地区(1990-2021)的年龄-性别特异性艾滋病毒死亡率、发病率和流行率估计值。我们的目的是分析所有可用的数据来源,包括向联合国艾滋病规划署报告的艾滋病毒规划的提供数据,通过系统评价确定的抗逆转录病毒治疗(ART)患者死亡率的已发表文献,家庭调查,哨点监测产前保健诊所数据,生命登记数据和国家级病例报告数据。我们根据现有数据校准了HIV感染和自然历史的机制模拟,以估计1990年至2021年的HIV负担,并通过对未来所有模拟输入的预测,生成了到2050年的预测。历史结果(1990-2021)在1000次抽取水平上进行模拟,以支持不确定性的传播和不确定性区间(ui)的报告。我们的预测方法利用传播率作为预测的基础,以及新的抗逆转录病毒治疗覆盖率变化率预测。此外,我们在报告中引入了两个新指标:未抑制病毒血症(PUV)患病率,它代表了未抑制HIV水平的人口比例(病毒载量发现:2010年至2021年间,全球新发HIV感染减少了21.9% (95% UI 13.1 - 28.8),从2010年的211万(20.02 - 2.25)降至2021年的165万(1.48 - 1.82)。与艾滋病毒相关的死亡人数减少了39.7%(33.7 - 44.5),从2010年的1.19万人(1.07 - 1.37人)减少到2021年的71.8万人(66.9 - 78.5万人)。艾滋病毒发病率和死亡率下降幅度最大的是撒哈拉以南非洲和南亚。然而,包括中欧、东欧和中亚以及北非和中东在内的超级区域的艾滋病毒发病率和死亡率不断上升。艾滋病毒感染者人数从2010年的2950万(28.1 - 31.0)增加到2021年的4000万(38.0 - 42.4)。撒哈拉以南非洲超级区域终生感染艾滋病毒的概率仍然最高,从1995年21.8%(20.1 - 24.2)的峰值下降到2021年的8.7%(7.5 - 10.7)。到2021年,七个GBD超级区域中有四个的终生概率低于1%。2021年,撒哈拉以南非洲的PUV最高,为每10万人999·9(857·4-1154·2),但从2003年到2021年,PUV减少了64.5%(58·8- 669·4)。同期,中欧、东欧和中亚地区的PUV增长了11.1%(8.0% ~ 21.2%)。我们的预测显示,全球艾滋病毒发病率和死亡率将持续下降,到2039年,艾滋病毒感染者人数将达到4440万(407 - 498)的峰值,随后逐渐减少。到2025年,我们预计将有143万(1.29 - 1.59)例新的艾滋病毒感染和61.5万(567 -68万)例与艾滋病毒相关的死亡,这表明减少这些数字的2025年中期目标不太可能实现。此外,我们的预测结果表明,很少有国家能够实现2030年将艾滋病毒发病率和与艾滋病毒相关的死亡人数在2010年的基础上减少90%的目标。解释:我们的预测表明,如果继续保持目前的艾滋病毒控制水平,到2030年不太可能实现降低发病率和死亡率的宏伟目标,在未来几十年里,全球将有4000多万人继续需要终身抗逆转录病毒治疗。国际社会将需要显示出持续和实质性的努力,以取得必要的进展,实现并维持终结艾滋病这一公共威胁的目标。资助:比尔和梅林达·盖茨基金会和国家过敏和传染病研究所。
{"title":"Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021.","authors":"","doi":"10.1016/S2352-3018(24)00212-1","DOIUrl":"10.1016/S2352-3018(24)00212-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;As set out in Sustainable Development Goal 3.3, the target date for ending the HIV epidemic as a public health threat is 2030. Therefore, there is a crucial need to evaluate current epidemiological trends and monitor global progress towards HIV incidence and mortality reduction goals. In this analysis, we assess the current burden of HIV in 204 countries and territories and forecast HIV incidence, prevalence, and mortality up to 2050 to allow countries to plan for a sustained response with an increasing number of people living with HIV globally.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 analytical framework to compute age-sex-specific HIV mortality, incidence, and prevalence estimates for 204 countries and territories (1990-2021). We aimed to analyse all available data sources, including data on the provision of HIV programmes reported to UNAIDS, published literature on mortality among people on antiretroviral therapy (ART) identified by a systematic review, household surveys, sentinel surveillance antenatal care clinic data, vital registration data, and country-level case report data. We calibrated a mechanistic simulation of HIV infection and natural history to available data to estimate HIV burden from 1990 to 2021 and generated forecasts to 2050 through projection of all simulation inputs into the future. Historical outcomes (1990-2021) were simulated at the 1000-draw level to support propagation of uncertainty and reporting of uncertainty intervals (UIs). Our approach to forecasting utilised the transmission rate as the basis for projection, along with new rate-of-change projections of ART coverage. Additionally, we introduced two new metrics to our reporting: prevalence of unsuppressed viraemia (PUV), which represents the proportion of the population without a suppressed level of HIV (viral load &lt;1000 copies per mL), and period lifetime probability of HIV acquisition, which quantifies the hypothetical probability of acquiring HIV for a synthetic cohort, a simulated population that is aged from birth to death through the set of age-specific incidence rates of a given time period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Global new HIV infections decreased by 21·9% (95% UI 13·1-28·8) between 2010 and 2021, from 2·11 million (2·02-2·25) in 2010 to 1·65 million (1·48-1·82) in 2021. HIV-related deaths decreased by 39·7% (33·7-44·5), from 1·19 million (1·07-1·37) in 2010 to 718 000 (669 000-785 000) in 2021. The largest declines in both HIV incidence and mortality were in sub-Saharan Africa and south Asia. However, super-regions including central Europe, eastern Europe, and central Asia, and north Africa and the Middle East experienced increasing HIV incidence and mortality rates. The number of people living with HIV reached 40·0 million (38·0-42·4) in 2021, an increase from 29·5 million (28·1-31·0) in 2010. The lifetime probability of HIV acquisition","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e807-e822"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing HIV prevention and the PrEP gap among migrants. 解决移民中的艾滋病毒预防和 PrEP 差距。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1016/S2352-3018(24)00272-8
Christiana Nöstlinger
{"title":"Addressing HIV prevention and the PrEP gap among migrants.","authors":"Christiana Nöstlinger","doi":"10.1016/S2352-3018(24)00272-8","DOIUrl":"10.1016/S2352-3018(24)00272-8","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e798-e800"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights of the 5th HIVR4P Conference. 第 5 届 HIVR4P 会议要点。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1016/S2352-3018(24)00307-2
Adrian Gonzalez-Lopez
{"title":"Highlights of the 5th HIVR4P Conference.","authors":"Adrian Gonzalez-Lopez","doi":"10.1016/S2352-3018(24)00307-2","DOIUrl":"10.1016/S2352-3018(24)00307-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e806"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet HIV 2024; 11: e64-65. Lancet HIV 2024; 11: e64-65 更正。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-03-28 DOI: 10.1016/S2352-3018(24)00091-2
{"title":"Correction to Lancet HIV 2024; 11: e64-65.","authors":"","doi":"10.1016/S2352-3018(24)00091-2","DOIUrl":"10.1016/S2352-3018(24)00091-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e804"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiretrovirals and obesity. 抗逆转录病毒药物与肥胖。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-29 DOI: 10.1016/S2352-3018(24)00298-4
Nikos Pantazis, Kholoud Porter, Caroline A Sabin, Fiona Burns, Giota Touloumi
{"title":"Antiretrovirals and obesity.","authors":"Nikos Pantazis, Kholoud Porter, Caroline A Sabin, Fiona Burns, Giota Touloumi","doi":"10.1016/S2352-3018(24)00298-4","DOIUrl":"10.1016/S2352-3018(24)00298-4","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e802-e803"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extreme weather events and disruptions to HIV services: a systematic review. 极端天气事件与艾滋病服务中断:系统回顾。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-09 DOI: 10.1016/S2352-3018(24)00186-3
Collins C Iwuji, Celia McMichael, Euphemia Sibanda, Kingsley S Orievulu, Kelly Austin, Kristie L Ebi

Background: Extreme weather events pose a risk to health and disproportionately affect vulnerable groups, such as people living with HIV. We aimed to investigate the effects of extreme weather events on HIV testing uptake, HIV treatment and care, and HIV transmission.

Methods: For this systematic review, we searched PubMed, Web of Science, and PsycINFO for peer-reviewed studies published between database inception and Aug 31, 2023. Eligible studies were English-language qualitative, quantitative observational (retrospective, prospective, cross-sectional, longitudinal, case-control, and cohort), and mixed-method studies, and randomised controlled trials related to HIV and extreme weather events. We excluded reviews, mathematical models, and case reports. After exporting the search results, two authors independently screened the titles and abstracts of identified articles, reviewing the full text of those that met the inclusion criteria. We used systems thinking to develop a framework linking extreme weather events and HIV and summarised the results using thematic narrative synthesis.

Findings: Of the 6126 studies identified by the search, 27 met the inclusion criteria and were eligible for analysis, of which 19 were quantitative, six were qualitative, and two were mixed-method studies. We identified five main themes linking extreme weather events to HIV: economic and livelihood conditions (12 studies), psychosocial factors (19 studies), infrastructure damage and operational challenges (17 studies), migration and displacement (ten studies), and associated medical conditions and health-care needs (12 studies). We showed how these themes interact in complex ways, resulting in a reduction in uptake of HIV testing, interruption of HIV care and subsequent disease progression, altered risk behaviours, and an increased prevalence of HIV.

Interpretation: Extreme weather events are associated with disruptions to HIV services. Owing to the design of the included studies, we could not establish a causal relationship between extreme weather events and HIV incidence, highlighting a research gap. Appropriate adaptations and mitigation policies that protect the health and wellbeing of people living with HIV during and after extreme weather events are warranted. Such actions will be crucial to achieving the UNAIDS goal of ending HIV as a public health threat by 2030.

Funding: None.

背景:极端天气事件对健康构成风险,对弱势群体(如艾滋病毒感染者)的影响尤为严重。我们旨在调查极端天气事件对艾滋病检测率、艾滋病治疗和护理以及艾滋病传播的影响:在本系统性综述中,我们检索了 PubMed、Web of Science 和 PsycINFO 上从数据库开始到 2023 年 8 月 31 日之间发表的同行评审研究。符合条件的研究包括与 HIV 和极端天气事件相关的英语定性、定量观察(回顾性、前瞻性、横断面、纵向、病例对照和队列)、混合方法研究和随机对照试验。我们排除了综述、数学模型和病例报告。导出搜索结果后,两位作者独立筛选了已确定文章的标题和摘要,并审阅了符合纳入标准的文章全文。我们利用系统思维建立了一个将极端天气事件与艾滋病联系起来的框架,并利用主题叙述综合法对结果进行了总结:在搜索确定的 6126 篇研究中,有 27 篇符合纳入标准,可以进行分析,其中 19 篇为定量研究,6 篇为定性研究,2 篇为混合方法研究。我们确定了将极端天气事件与艾滋病联系起来的五大主题:经济和生计条件(12 项研究)、社会心理因素(19 项研究)、基础设施破坏和运营挑战(17 项研究)、移民和流离失所(10 项研究)以及相关的医疗条件和保健需求(12 项研究)。我们展示了这些主题如何以复杂的方式相互作用,导致艾滋病检测率下降、艾滋病护理中断和随后的疾病进展、风险行为改变以及艾滋病流行率上升:极端天气事件与艾滋病服务中断有关。由于所纳入研究的设计原因,我们无法确定极端天气事件与艾滋病发病率之间的因果关系,这凸显了研究缺口。有必要采取适当的适应和缓解政策,在极端天气事件发生期间和之后保护艾滋病毒感染者的健康和福祉。这些行动对于实现联合国艾滋病规划署到 2030 年消除艾滋病毒对公众健康的威胁这一目标至关重要:资金:无。
{"title":"Extreme weather events and disruptions to HIV services: a systematic review.","authors":"Collins C Iwuji, Celia McMichael, Euphemia Sibanda, Kingsley S Orievulu, Kelly Austin, Kristie L Ebi","doi":"10.1016/S2352-3018(24)00186-3","DOIUrl":"10.1016/S2352-3018(24)00186-3","url":null,"abstract":"<p><strong>Background: </strong>Extreme weather events pose a risk to health and disproportionately affect vulnerable groups, such as people living with HIV. We aimed to investigate the effects of extreme weather events on HIV testing uptake, HIV treatment and care, and HIV transmission.</p><p><strong>Methods: </strong>For this systematic review, we searched PubMed, Web of Science, and PsycINFO for peer-reviewed studies published between database inception and Aug 31, 2023. Eligible studies were English-language qualitative, quantitative observational (retrospective, prospective, cross-sectional, longitudinal, case-control, and cohort), and mixed-method studies, and randomised controlled trials related to HIV and extreme weather events. We excluded reviews, mathematical models, and case reports. After exporting the search results, two authors independently screened the titles and abstracts of identified articles, reviewing the full text of those that met the inclusion criteria. We used systems thinking to develop a framework linking extreme weather events and HIV and summarised the results using thematic narrative synthesis.</p><p><strong>Findings: </strong>Of the 6126 studies identified by the search, 27 met the inclusion criteria and were eligible for analysis, of which 19 were quantitative, six were qualitative, and two were mixed-method studies. We identified five main themes linking extreme weather events to HIV: economic and livelihood conditions (12 studies), psychosocial factors (19 studies), infrastructure damage and operational challenges (17 studies), migration and displacement (ten studies), and associated medical conditions and health-care needs (12 studies). We showed how these themes interact in complex ways, resulting in a reduction in uptake of HIV testing, interruption of HIV care and subsequent disease progression, altered risk behaviours, and an increased prevalence of HIV.</p><p><strong>Interpretation: </strong>Extreme weather events are associated with disruptions to HIV services. Owing to the design of the included studies, we could not establish a causal relationship between extreme weather events and HIV incidence, highlighting a research gap. Appropriate adaptations and mitigation policies that protect the health and wellbeing of people living with HIV during and after extreme weather events are warranted. Such actions will be crucial to achieving the UNAIDS goal of ending HIV as a public health threat by 2030.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e843-e860"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ending barriers to HIV care for migrant populations. 消除流动人口获得艾滋病毒护理的障碍。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 DOI: 10.1016/S2352-3018(24)00316-3
The Lancet Hiv
{"title":"Ending barriers to HIV care for migrant populations.","authors":"The Lancet Hiv","doi":"10.1016/S2352-3018(24)00316-3","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00316-3","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"11 12","pages":"e791"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Hiv
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1